Discovery STREAM
-
Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin
9/7/2023
Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”
-
The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation
4/14/2022
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
-
Saudi Arabia Government Leaders Discuss Agile Manufacturing Beyond Borders
10/23/2022
Learn how government leaders in Saudi Arabia planned for biopharma resilience beyond borders and used agile manufacturing to prepare for the unknown.
-
Pragmatic Computational Biology with Andrew Satz
9/20/2023
This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?
-
BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D.
2/26/2023
Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here.
-
Nanoassemblr Blaze mRNA Vaccine Demo
4/13/2022
NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process.
-
Is The Sensitivity Of Optical Biosensors Important?
2/17/2022
Explore why the sensitivity of optical biosensors is important for not just small molecules or fragment-based interactions but also for larger molecular entities.
-
The NanoAssemblr® Spark™ Instrument Demo
4/13/2022
The NanoAssemblr® Spark™ uses proprietary microfluidics technology for the controlled and reproducible manufacturing of nanoparticles in small volumes in less than 10 seconds.
-
Testing Liquid Handler Performance With PCRMix
5/6/2022
We demonstrate the importance of using an appropriate test solution when optimizing a liquid handler to dispense the master mix, a critical component in any PCR-based assay.